Roche Venture Fund was among the existing investors that helped supply $50m for Arch Oncology, the cancer drug developer formerly known as Tioma.
US-based immuno-oncology therapy developer Arch Oncology collected $50m on Monday in a series B round that included Roche Venture Fund, the corporate venturing unit operated by pharmaceutical firm Roche.
The round was led by Lightchain, the family office for Rodger Riney, founder of stock brokerage Scottrade, which participated alongside investment firm RiverVest Venture Partners and venture capital firm 3×5 Partners.
Formerly known as Tioma Therapeutics, Arch Oncology is developing therapies that are intended to treat cancer by using the patient’s…
